Retatrutide vs Semaglutide: Three Receptors Against One

Two peptides sit at opposite ends of the incretin era. Semaglutide is a pure GLP-1 monoagonist with one of the deepest clinical evidence bases in modern metabolic medicine, including a cardiovascular outcomes trial in tens of thousands of participants. Retatrutide (LY3437943) is a single-molecule triple agonist hitting GIP, GLP-1, and glucagon receptors at once, and in Phase 2 it produced the largest weight loss ever documented for a pharmacological intervention. One is the reference standard. The other is the frontier. This article compares them not just on headline numbers but on the axis that actually matters for research: how much weight the evidence carries versus how large the effect is.

Research and educational use only. Retatrutide is an investigational compound and is not approved by the FDA or any regulatory body for human use. Semaglutide is approved for specific indications, but nothing here is medical advice or a dosing recommendation. This article describes what the peer-reviewed literature documents.

The Core Contrast: Three Receptors Against One

The single most important difference between these two compounds is the number of receptors each one activates. That number is not a trivia point. It is the mechanistic reason the efficacy ceilings are different.

Semaglutide is a GLP-1 analogue. It engages one arm of the incretin system: GLP-1 receptors in the pancreas (glucose-dependent insulin release), the gut (delayed gastric emptying), and the brain (satiety signaling through the area postrema and hypothalamus). That single pathway built the modern obesity-pharmacology field.

Retatrutide keeps that GLP-1 arm and adds two more. The GIP component (shared with tirzepatide) modulates adipocyte biology and amplifies GLP-1 satiety signaling in the hypothalamus. The glucagon component is the genuinely new lever, and it is what separates retatrutide from everything before it.

Why Adding GIP and Glucagon Raises the Efficacy Ceiling

Semaglutide works almost entirely through the appetite side of the energy-balance equation. It reduces energy intake, a real and large effect, but one with a natural ceiling: you can only suppress appetite so far before tolerability breaks down, and the body defends its weight by lowering energy expenditure as intake falls.

Retatrutide attacks both sides. The glucagon receptor arm does something GLP-1 cannot: it increases energy expenditure. Glucagon receptor agonism drives hepatic fatty acid oxidation, raises basal metabolic rate, and promotes lipolysis. On its own, glucagon is hyperglycemic and would worsen metabolic outcomes. The elegance of the triple design is that simultaneous GLP-1 receptor activation drives glucose-dependent insulin secretion, which offsets glucagon's glucose-raising effect. The result: you capture glucagon's thermogenic, fat-oxidizing benefits without the glycemic penalty.

This is the mechanistic reason the efficacy ceiling moves. Semaglutide pulls one lever hard. Retatrutide pulls three, and one of those three works on a completely different axis (expenditure, not just intake). That is why the weight loss numbers are not merely a little higher, they are in a different tier.

• Semaglutide: intake down, expenditure defends against loss
• Retatrutide: intake down (GLP-1 + GIP) AND expenditure up (glucagon)

For the deeper mechanistic breakdown of the triple design, see retatrutide triple agonist research: what the studies show.

Weight Loss: The Numbers and the Cross-Trial Caveat

Here is the headline comparison, and here is the caveat that has to travel with it every single time.

The caveat: these are different trials. Retatrutide's -24.2% comes from a 338-person Phase 2 study over 48 weeks. Semaglutide's -14.9% comes from STEP-1, a Phase 3 trial in nearly 2,000 people over 68 weeks. There has never been a head-to-head trial of retatrutide against semaglutide. Different populations, different durations, different trial phases, different placebo responses. You cannot subtract one number from the other and call the difference "9.3% more weight loss." You can say retatrutide's Phase 2 curve is steeper and higher, which is a directional observation, not a quantified head-to-head delta.

A second detail worth its own line: retatrutide's 12 mg arm was still losing weight at 48 weeks. At 24 weeks that arm was around -17.5%, and by 48 weeks it reached -24.2%, meaning the curve had not yet clearly plateaued. STEP-1's semaglutide curve is closer to flattening by 68 weeks. That trajectory difference is one of the most interesting open questions in the field, and it is exactly why the Phase 3 TRIUMPH program matters. For a week-by-week view of the retatrutide curve, see the results timeline.

Responder Distribution

Averages hide the story. Response thresholds are where the clinical meaning lives.

• Retatrutide 8 mg and 12 mg: 100% of participants reached at least 5% weight loss at 48 weeks in Phase 2
• Retatrutide 12 mg: roughly 26% reached at least 30% weight loss, a range historically associated only with bariatric surgery
• Semaglutide 2.4 mg in STEP-1: the majority reached 5% and 10%, but the fraction reaching 20%+ was a minority

The reason the responder curves matter more than the mean: comorbidities remit at thresholds. Moving the center of the responder distribution past the 25% to 30% mark shifts a meaningful minority of subjects into a weight-loss range where conditions like severe steatohepatitis and obstructive sleep apnea meaningfully improve.

Glycemic Effect: HbA1c Head to Head (Within Class)

On the diabetes side, retatrutide's Phase 2 type 2 diabetes trial (Rosenstock et al., The Lancet 2023, n=281, 36 weeks) is the reference point.

Retatrutide's -2.02% HbA1c reduction at 12 mg is notable because it beat the active comparator (dulaglutide) inside the same trial, which is a cleaner comparison than any cross-trial figure. Semaglutide's HbA1c reductions in its own diabetes trials fall in a well-characterized range and are backed by far more data. The point is not that retatrutide "wins" glycemic control; it is that retatrutide's glucagon arm did not sabotage glucose control despite glucagon being intrinsically hyperglycemic. That is the mechanistic proof-of-concept the trial was designed to test.

Liver Fat: Where the Glucagon Arm Shows Off

This is the area where the mechanism contrast is most visible in the data. A 2023 liver fat substudy reported that retatrutide reduced liver fat content by up to roughly 86% at 24 weeks in participants with MASLD, with about 80% of participants reaching normal liver fat content (under 5%).

That magnitude is a direct readout of glucagon receptor agonism driving hepatic fatty acid oxidation. Semaglutide also reduces liver fat and is being studied in steatohepatitis, but through the GLP-1 pathway (largely a consequence of weight loss and improved insulin sensitivity) rather than a direct hepatic fat-burning signal. The triple agonist has a mechanistic advantage on the liver specifically because glucagon acts directly on hepatocytes. For researchers whose endpoint is liver fat, this is the single strongest argument for the triple agonist over the monoagonist.

Half-Life, Dosing, and Pharmacokinetics

Both compounds are engineered for once-weekly subcutaneous dosing, and their pharmacokinetics are close enough that dosing frequency is not a differentiator.

The roughly 6-day half-life of retatrutide comfortably supports once-weekly dosing with stable steady-state exposure, the same logic that governs semaglutide's roughly 7-day half-life. Both require slow dose titration, and for both the gastrointestinal side effects are worst during the escalation phase, not at steady state.

Safety Profile: Depth of Characterization Is the Real Difference

The adverse event categories overlap heavily. Both are dominated by dose-dependent, mostly mild-to-moderate gastrointestinal effects that peak during titration.

The categories look similar. The confidence does not. Semaglutide's safety is characterized across Phase 3 trials, a dedicated cardiovascular outcomes trial (SELECT), kidney outcomes (FLOW), and years of real-world post-marketing surveillance. Retatrutide's safety profile is drawn from a Phase 2 dataset measured in hundreds of participants over months. The retatrutide heart-rate signal, a dose-dependent rise that peaked around 24 weeks then declined, is exactly the kind of finding that needs Phase 3 scale and duration to fully interpret. For the complete adverse-event breakdown, see the retatrutide side effects guide.

The Framework: Evidence Weight Versus Effect Size

Here is the information-gain argument at the center of this comparison. Semaglutide and retatrutide are not "better and worse" versions of the same thing. They occupy opposite corners of a two-axis map: how large the effect is, and how much the evidence can be trusted.

• Effect size axis: how much weight loss, HbA1c reduction, and liver fat clearance the compound produces. Retatrutide is ahead on all three in the available data.
• Evidence weight axis: how mature, replicated, and outcome-anchored the data is. Semaglutide is far ahead, with Phase 3 replication and hard cardiovascular endpoints.

The two compounds trade positions on these axes almost perfectly. Scoring each on five dimensions makes the trade explicit.

The scores are a heuristic, not a measurement, but the pattern is the point. Retatrutide dominates the efficacy row and loses every evidence, safety, and access row. Semaglutide is the mirror image. No dimension has one compound simply better across the board, which is why the choice for any research program depends on which axis the study endpoint sits on.

A concrete way to use the framework: if a question is about the largest achievable metabolic effect or direct hepatic fat oxidation, the effect-size axis dominates and retatrutide is the more interesting subject. If a question needs a well-characterized comparator, a known safety envelope, or an outcome-anchored benchmark, the evidence-weight axis dominates and semaglutide is the correct reference. Use the comparison quiz to think through which axis a question sits on, and the dosing calculator to model titration schedules for either compound.

Why Semaglutide Remains the Reference Standard

It would be easy to read the numbers and conclude semaglutide is obsolete. That conclusion is wrong, and understanding why is the most useful thing in this article.

Semaglutide is the reference standard precisely because of the evidence-weight axis, not despite it. Its lower raw weight loss number comes attached to a body of evidence that retatrutide will not match for years:

• Cardiovascular outcomes. The SELECT trial demonstrated a meaningful reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease. This is the first time an obesity pharmacotherapy proved a hard cardiovascular benefit. Retatrutide has no outcomes data at all. Weight loss is a surrogate endpoint; a MACE reduction is an outcome.
• Replication across indications. Semaglutide has documented effects in obesity (STEP program), type 2 diabetes, heart failure with preserved ejection fraction (STEP-HFpEF), and kidney outcomes (FLOW). Breadth of replicated evidence is itself a form of validity.
• Known safety envelope. Years of post-marketing surveillance mean rare adverse events have had time to surface. A Phase 2 dataset simply cannot rule out low-frequency risks.
• Comparability. Because semaglutide is so thoroughly characterized, it functions as the anchor other compounds are measured against. A number is only interpretable relative to a well-understood reference, and semaglutide is that reference.

The correct reading: retatrutide has the higher effect size, semaglutide the higher evidentiary confidence, and effect size without confidence is a hypothesis, not a conclusion. Retatrutide's -24.2% is genuinely spectacular AND it is a Phase 2 result awaiting confirmation. Both are true at once.

Availability and Legal Status

This is where the practical gap is widest, and where the most caution is required.

Semaglutide is an approved medication with a regulated supply chain and defined indications. Retatrutide is investigational. It is not approved anywhere for human use, and its Phase 3 TRIUMPH program (TRIUMPH-1 through TRIUMPH-4 plus a cardiovascular outcomes study) is still ongoing.

Because retatrutide is not approved, it circulates in the research-chemical grey market, frequently under the nicknames "GLP-3" or "triple G." A blunt clarification: there is no such thing as a GLP-3 receptor. "GLP-3" is marketing shorthand invented by sellers, not a real receptor class. The compound is a GIP/GLP-1/glucagon triple agonist, and any vendor using "GLP-3" as a scientific term is signaling marketing over accuracy. If you are evaluating sourcing, read where to buy retatrutide and the vetted vendor directory first, and note that grey-market material carries purity and identity risks approved semaglutide does not.

Which Compound Fits Which Research Question

A decision framework rather than a recommendation:

• Endpoint is cardiovascular outcomes or hard clinical events: semaglutide, because it is the only one of the two with outcomes data.
• Endpoint is maximum weight loss magnitude: retatrutide shows the steeper Phase 2 curve, with the caveat that it is Phase 2.
• Endpoint is direct hepatic fat oxidation or MASLD: retatrutide, because the glucagon arm acts directly on the liver.
• You need a well-characterized safety envelope: semaglutide, by a wide margin.
• You need a reference comparator to benchmark other compounds: semaglutide, the field standard.
• You are studying novel triple-agonist pharmacology itself: retatrutide is the whole point.

Work through the full peptide fundamentals in the learn hub, and if you are running a structured protocol, the tracker is built to log titration and response data over time.

Frequently Asked Questions

Is retatrutide better than semaglutide?

It depends entirely on which axis you weigh. Retatrutide produced larger weight loss in Phase 2 (-24.2% at 48 weeks versus semaglutide's -14.9% at 68 weeks in STEP-1), but semaglutide has vastly more mature evidence, including cardiovascular outcomes data, and is an approved medication. Higher effect size does not equal higher confidence, so "better" is not a single answer.

Can I directly compare the -24.2% and -14.9% numbers?

No, and this matters. Those figures come from different trials with different populations, durations, and trial phases, and there has never been a head-to-head study. The comparison is directional at best. Retatrutide's Phase 2 curve is steeper and higher, but you cannot subtract the numbers and claim a precise difference.

What does the extra glucagon receptor actually do?

Glucagon receptor agonism increases energy expenditure by driving hepatic fatty acid oxidation and raising basal metabolic rate, which is a completely different mechanism from GLP-1's appetite suppression. On its own glucagon raises blood sugar, but simultaneous GLP-1 activation triggers glucose-dependent insulin secretion that offsets that effect. This is why retatrutide can capture glucagon's fat-burning benefit without a glycemic penalty.

Why is retatrutide called "GLP-3" or "triple G"?

Those are grey-market marketing nicknames, not scientific terms. There is no GLP-3 receptor; retatrutide is a triple agonist of the GIP, GLP-1, and glucagon receptors. Any vendor treating "GLP-3" as real terminology is prioritizing marketing over accuracy.

Which one is safer?

Both are dominated by dose-dependent gastrointestinal side effects that peak during titration, so their adverse-event categories look similar. The real difference is confidence: semaglutide's safety is characterized across Phase 3 trials, an outcomes trial, and years of post-marketing data, while retatrutide's profile is based on Phase 2 data measured over months. Semaglutide's safety is far better characterized, which is not the same as retatrutide being unsafe.

Does retatrutide help with fatty liver more than semaglutide?

The mechanism suggests yes for liver fat specifically. A 2023 substudy reported retatrutide reduced liver fat by up to roughly 86% at 24 weeks in MASLD participants, with about 80% reaching normal liver fat content, driven by direct glucagon action on hepatocytes. Semaglutide also reduces liver fat but through the indirect GLP-1 pathway rather than a direct hepatic fat-burning signal.

When will there be real head-to-head data?

Retatrutide's Phase 3 TRIUMPH program is ongoing and will define its efficacy and safety at scale, but a direct head-to-head against semaglutide at obesity doses has not been published. Until such a trial exists, all comparisons remain cross-trial and directional. Follow the blog for updates as the evidence matures.

Key Research Citations

Retatrutide and semaglutide are the clearest illustration in metabolic pharmacology of the difference between effect size and evidence weight. The triple agonist is the more powerful molecule on paper; the monoagonist is the more trustworthy one in practice. As the TRIUMPH program reports out, the gap on the evidence axis will narrow. Until then, treat the numbers with the caveats they deserve.